Following injection of the compound to U87MG.wt EGFR tumor-bearing mice (5 mg/kg i.v.), ML04 demonstrated significant inhibition of EGFR phosphorylation levels in tumors in vivo at different time points post administration. The gene discussed is EGFR; the disease is neoplasm.